| Immuno-Oncology | PreClinical | Clinical | Rights | |
|---|---|---|---|---|
| Fate-NK100 – AML |
|
Worldwide | ||
| Fate-NK100 – Ovarian |
|
Worldwide | ||
| Fate-NK100 – Solid Tumor mAb Combo |
|
Worldwide | ||
| FT500 (iNK Cell)1 |
|
Worldwide | ||
| FT516 (Engineered hnCD16 iNK Cell)1 |
|
Worldwide | ||
| FT538 (Engineered CD38- iNK Cell)1 |
|
Worldwide | ||
| FT819 (Engineered CAR19 iT Cell)1 |
|
Worldwide | ||
| Ex Vivo T-Cell Modulation Collaboration2 |
|
Milestone / Royalties | ||
| IMMUNO-REGULATION | ||||
| ProTmune™ – Graft-versus-Host Disease |
|
Worldwide | ||
| ToleraCyte™ – Autoimmune Disorders |
|
Worldwide | ||
| FT300 (iMDS Cell)1 |
|
Worldwide | ||
| Immuno-Oncology | Phase | Rights | ||
|---|---|---|---|---|
| Fate-NK100 – AML | Phase 1 | Worldwide | ||
| Fate-NK100 – Ovarian | Phase 1 | Worldwide | ||
| Fate-NK100 – Solid Tumor mAb Combo | Phase 1 | Worldwide | ||
| FT500 (iNK Cell)1 | Preclinical | Worldwide | ||
| FT516 (Engineered hnCD16 iNK Cell)1 | Preclinical | Worldwide | ||
| FT538 (Engineered CD38- iNK Cell)1 | Preclinical | Worldwide | ||
| FT819 (Engineered CAR19 iT Cell)1 | Preclinical | Worldwide | ||
| Ex Vivo T-Cell Modulation Collaboration2 | Preclinical | Milestone / Royalties | ||
| IMMUNO-REGULATION | ||||
| ProTmune™ – Graft-versus-Host Disease | Phase 2 | Worldwide | ||
| ToleraCyte™ – Autoimmune Disorders | Preclinical | Worldwide | ||
| FT300 (iMDS Cell)1 | Preclinical | Worldwide | ||
1. Off-the-Shelf (OTS) using Clonal Master Induced Pluripotent Stem Cell (iPSC) Lines.
2. Collaboration excludes all cell types derived from induced pluripotent stem cells including engineered T cells.